Evaxion's EVX-01 shows durable clinical outcomes in three-year phase 2 melanoma data
EVAX•Evaxion reported three-year phase 2 data for its personalized cancer vaccine EVX-01, describing durable clinical outcomes and immune system activation in patients with advanced melanoma. The results were presented at the European Society for Medical Oncology Congress in Madrid.
1. Three-year results
Evaxion reported three-year phase 2 data for EVX-01, its personalized cancer vaccine for advanced melanoma, describing durable clinical outcomes and immune system activation. The results were presented at the European Society for Medical Oncology Congress in Madrid.
2. Platform and candidate
EVX-01 is the most advanced drug candidate developed using Evaxion's AI-Immunology platform. The platform received the 2026 International Prix Galien award for best digital health solution.
